Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.

Raccontata dabenzinga.com